India initiates probe against alleged API dumping by China
India has initiated a probe into alleged dumping of an active pharmaceutical ingredient (API), ceftriaxone sodium sterile, from China, following complaints by domestic manufacturers.
India’s Directorate General of Trade Remedies is looking into allegations that the concerned API is being dumped in the country. The probe has been initiated due to complaints filed by Indian pharma firms Nectar Life Sciences (BSE: NSE) and Sterile India, which have sought the imposition of an anti-dumping duty on the product.
According to the DGTR notification, the applicants have contended that material injury is being caused to the domestic industry due to the dumped imports from China. In the probe, the directorate will determine the existence, degree and effect of alleged dumping in respect of the product from China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze